Osteoarthritis is an incapacitating condition with diverse etiologies, the most recently described of which is metabolic syndrome (MetS). For the first time, researchers from the “Molecular Engineering and Articular Physiopathology” (Cnrs/Université de Lorraine) and “Acute and chronic cardiovascular failure” (Inserm/Université de Lorraine) research laboratories in Nancy, France, have described the spontaneous development of this type of degenerative joint disease in a mouse model of MetS. Inserm researchers Hervé Kempf and Anne Pizard, together with their co-workers, have characterized the existence of osteoarthritic lesions of the tibiofemoral joint of the knee in the presence of metabolic disorders.
This new experimental model of metabolic-associated osteoarthritis has also made it possible to demonstrate that chronic treatment with a mineralocorticoid receptor antagonist (MCRA) improves joint impairment. This drug is already used in heart failure and has been proposed as possibly being more effective in obese patients.
This research has been the subject of a letter published in Annals of the Rheumatic Diseases.
For the researchers, “these results will make it possible to propose metabolic-associated osteoarthritis as a potential new indication for MCRA therapy”, a hypothesis that they intend to test in the clinical setting very soon.
Inserm Transfert has filed a patent application for this research.
Mixed Research Unit "Molecular Engineering and Articular Physiopathology", Vandoeuvre-lès-Nancy, France
+33 (0) 3 83 68 54 26
Multi-theme CIC Unit 1433, Nancy University Hospital and INSERM U1116 "Acute and chronic cardiovascular failure", Vandoeuvre-lès-Nancy, France
+33 (0) 3 83 15 52 97
Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis, Annals of the Rheumatic DiseasesChaohua Deng1,2, Arnaud Bianchi1,2, Nathalie Presle1,2, David Moulin1,2,3, Meriem Koufany1,2, Cécile Guillaume1, Anne Pizard2,3,4,5, Hervé Kempf1,2
UMR7365 CNRS-Université de Lorraine, IMoPA, Ingénierie Moléculaire et Physiopathologie Articulaire, Vandoeuvre-les-Nancy, France
Fédération de Recherche 3209, Vandoeuvre-les-Nancy, France
CHRU Nancy, Vandoeuvre-les-Nancy, France
UMRS-Inserm U1116, Université de Lorraine, Vandoeuvre-les-Nancy, France
CIC-P1433 Inserm, CHRU Nancy, Vandoeuvre-les-Nancy, France